CA
Caris Life Sciences, Inc.
CAI · NASDAQ
$30.92 +7.81% (+$2.24)
1M +34.53%
Market Cap $7.97B
P/E Ratio 75.85x
Div. Yield -
ROE 18.77%
Piotroski F-Score Moderate
5/9Valuation
0 /100
Expensive P/S 8.06x
P/E 75.85x
P/B 13.48x
Growth
100 /100
Growing Rev. growth 46.46%
Book val. growth N/A
EPS growth N/A
Profitability
79 /100
Strong Op. margin 15.49%
Gross margin 69.66%
FCF margin 14.80%
Quality
79 /100
Excellent ROA 8.55%
ROIC 14.69%
Asset turnover 0.80x
Debt
78 /100
Low Int. coverage 3.24x
Debt/Equity 0.76x
Net debt/EBITDA -1.38x
Stability
41 /100
Moderate EPS volatility 39.17%
Beta 0.68x
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre CAI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Dean Halbert
Employees
1,846
Headquarters
Irving
Evenimente viitoare
04 NOV.
Earnings
Upcoming earnings report